Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Hok Bing Thio
Erasmus Medical Center, Netherlands
Posters & Accepted Abstracts: Clin Exp Dermatol Res
Glatiramer acetate (GA) and interferon-beta (IFN-�²) are disease-modifying therapies (DMTs) for multiple sclerosis (MS) that are administrated via subcutaneous (SC) or intramuscular (IM) injections. Cutaneous adverse events associated with DMTs are common and may have a major impact patient's quality of life. DMTs for MS are frequently associated with local injection-site reactions and a wide spectrum of generalized cutaneous adverse events, in particular, the subcutaneous formulations. The most common cutaneous events were local injection site reactions and lipoatrophy. Systematic review reveals sixty five case reports involving 106 MS patients described a wide spectrum of cutaneous adverse events, the most frequently reported being lipoatrophy, cutaneous necrosis and ulcers and various immunemediated inflammatory skin diseases. Although some of the skin reactions may be severe and persistent, most of them are mild. We also performed the derMiS study, a cross sectional study conducted in 15 Dutch clinics. Eligible for inclusion were MS patients who had been treated with their first DMT for at least 2 years. Cutaneous events were assessed from digital photographs of injection sites by dermatologists blinded to DMT. A total of 229 patients were enrolled, of whom 44 (19%) were treated with SC GA, 60 (26%) with SC IFN-b-1b, 66 (29%) with SC IFN-b-1a and 59 (26%) with IM IFN-�²-1a. Mean duration of DMT treatment was 6 years (range 2-18 years). Overall, 156 (68%) had at least one cutaneous adverse event. The prevalence of cutaneous adverse events was higher for the SC DMTs (75 to 82%) compared to IM DMT (41%, P<0.001). Local injection site reactions (erythema and ecchymosis) and lipoatrophy were the most common skin reactions, occurring in 156 (68%) and 45 (20%) patients, respectively. Less frequently occurring reactions were post-inflammatory hyperpigmentation (7%), eczema (6%), healed ulcers (3%), urticaria (2%) and skin necrosis (0.4%). Topical therapy with a potent corticosteroid, tacrolimus or vitamin D can all be beneficial in counteracting these benign cutaneous adverse events. The additional use of any emollients is recommended. Also topical brimonidine can be an interesting option in order to prevent the erythema as cutaneous adverse event of interferon therapy in MS.
Email: h.thio@erasmusmc.nl